2021 High quality Sofosbuvir - Vonoprazan Fumarate (TAK-438) CAS 1260141-27-2 881681-01-2 API High Quality – Ruifu

Supply Vonoprazan Fumarate and Related Intermediate
5-(2-Fluorophenyl)pyrrole-3-Carboxaldehyde CAS 881674-56-2
Pyridine-3-Sulfonyl Chloride CAS 16133-25-8
Vonoprazan Fumarate (TAK-438) CAS 1260141-27-2 881681-01-2

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer’s requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture.

Vonoprazan Fumurate (TAK-438) (CAS: 1260141-27-2; 881681-01-2), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H+,K+-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan Fumarate (Takecab), discovered and developed by Takeda and Otsuka, was approved by the PMDA of Japan in December 2014. Vonoprazan Fumarate is mainly used for the treatment of helicobacter pylori infection, gastroesophageal reflux, peptic ulcer, duodenal ulcer, esophagitis, gastric ulcer and other gastric acid related diseases. The product has a strong, lasting inhibition of gastric acid secretion. At the treatment dose, Vonoprazan Fumarate has little effect on other enzymes and little effect on physiological functions of the body. It is safe and more tolerable.